Close Menu

NEW YORK – Bristol Myers Squibb said on Friday that the US Food and Drug Administration approved the combination of PD-1 inhibitor nivolumab (Opdivo) and CTLA-4 inhibitor ipilimumab (Yervoy) as a first-line treatment for PD-L1 expressing, metastatic non-small cell lung cancer with no EGFR or ALK mutations, as determined by an FDA-approved test.

The FDA also approved the PD-L1 IHC 28-8 pharmDx by Agilent Technologies as a companion diagnostic device for selecting NSCLC patients for treatment with the nivolumab and ipilimumab combination.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.